Anaptysbio (ANAB) Operating Income (2016 - 2026)
Anaptysbio's (ANAB) quarterly Operating Income came in at -$34.6 million in Q1 2026, down 25.77% YoY from -$46.7 million in Q1 2025, and down 151.77% on a QoQ basis from $66.9 million in Q4 2025.
Anaptysbio (ANAB) Operating Income (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Operating Income data on file, last reported at -$34.6 million in Q1 2026.
- Quarterly Operating Income fell 25.77% year-over-year to -$34.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.8 million (up 140.68% YoY) and the FY2025 annual result came in at $47.9 million, up 141.67% from the prior year.
- Operating Income declined to -$34.6 million in Q1 2026, from $66.9 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $66.9 million in Q4 2025 to a low of -$44.4 million in Q1 2023.
- A 5-year average of -$22.4 million and a median of -$29.6 million in 2022 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income tumbled 5115.57% — and 2025, when it soared 791.84%.
- Tracing ANAB's Operating Income over 5 years: stood at -$26.0 million in 2022, then tumbled by 62.23% to -$42.1 million in 2023, then surged by 77.05% to -$9.7 million in 2024, then jumped by 791.84% to $66.9 million in 2025, then plunged by 151.77% to -$34.6 million in 2026.
- The last three Operating Income figures came in at -$34.6 million (Q1 2026), $66.9 million (Q4 2025), and $34.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | -34.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.64 Mn |
| Dec 31, 2025 | 66.90 Mn |
| Sep 30, 2025 | 34.70 Mn |
| Jun 30, 2025 | -26.17 Mn |
| Mar 31, 2025 | -27.54 Mn |
| Dec 31, 2024 | -9.67 Mn |
| Sep 30, 2024 | -22.76 Mn |
| Jun 30, 2024 | -40.32 Mn |
| Mar 31, 2024 | -42.20 Mn |
| Dec 31, 2023 | -42.14 Mn |
| Sep 30, 2023 | -37.73 Mn |
| Jun 30, 2023 | -40.14 Mn |
| Mar 31, 2023 | -44.40 Mn |
| Dec 31, 2022 | -25.97 Mn |
| Sep 30, 2022 | -29.63 Mn |
| Jun 30, 2022 | -27.80 Mn |
| Mar 31, 2022 | -31.75 Mn |
| Dec 31, 2021 | -31.16 Mn |
| Sep 30, 2021 | -6.76 Mn |
| Jun 30, 2021 | -533,000.00 |